Follow-On Biologics Could Save Medicare $14 Bil. Over 10 Years – PCMA

Creating a way for FDA to approve follow-on biologics could lead to savings of more than $14 billion for Medicare Part B from fiscal 2007 to 2016, according to a "preliminary assessment" that the Pharmaceutical Care Management Association released Jan. 4